A Phase 3 interventional study of MP-424 and RBV(24 weeks) in Chronic Hepatitis C(CHC), sponsored by Tanabe Pharma Corporation. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 11th largest by enrollment, is one of 9 that started in 2012, is one of 12 in phase 3, and was the 20th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 54 across the 27 interventional studies. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 27 have an industry lead sponsor. The 10 most frequent:
Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
11 studies in Hepatitis C, Chronic by Tanabe Pharma Corporation: none open now, none under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 11 studies in Hepatitis C, Chronic by Tanabe Pharma Corporation, this one is the 5th largest by enrollment, is one of 3 that started in 2012, is one of 7 in phase 3, and was the 9th registered.
Tanabe Pharma Corporation’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tanabe Pharma Corporation’s 11 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MP-424 · Drug: RBV(24 weeks) · Drug: IFN beta(24 weeks)
Drug: RBV(48 weeks) · Drug: IFN beta(48 weeks)
Drug: MP-424 · Drug: RBV(24 weeks) · Drug: IFN beta(24 weeks)
MP-424: 750mg every 8 hours (q8h) for 12 weeks
RBV: 600 - 1000mg/day based on body weight for 24 weeks
Drug pages: Interferon beta · Interferon beta-1b · Interferon beta-1a
IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
RBV: 600 - 1000mg/day based on body weight for 48 weeks
Drug pages: Interferon beta · Interferon beta-1b · Interferon beta-1a
IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
Time frame: 72 weeks(RBV+IFN beta), 48 weeks(MP-424+RBV+IFN beta)
Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response)
Time frame: 4 weeks
Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response)
Time frame: 48 weeks(RBV+IFN beta), 24 weeks(MP-424+RBV+IFN beta)
Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration
Time frame: 60 weeks(RBV+IFN beta), 36 weeks(MP-424+RBV+IFN beta)
Transition of Serum HCV RNA Levels
Time frame: Baseline,Day2,Day3,1Week,2Weeks,3Weeks,4Weeks,12Weeks,End of treatment,Follow-up 12weeks,Follow-up 24weeks
Number of Participants With the Emergence of Resistance-associated Variants After MP-424 Administration at the Non-structural 3 Protease Region of HCV.
To examine the emergence of resistance-associated variants after MP-424 administration.
Time frame: From baseline to 24 weeks after completion of drug administration
| Milestone | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Started | 30 | 30 | 14 |
| Completed | 28 | 25 | 13 |
| Not completed | 2 | 5 | 1 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 0 |
| percentage of subjects achieving SVR | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) | 63.3 (43.9 to 80.1) | 20.0 (7.7 to 38.6) | 71.4 (41.9 to 91.6) |
| percentage of subjects achieving RVR | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Undetectable HCV RNA at 4 Weeks After Beginning of Drug Administration (RVR, Rapid Viral Response) | 70.0 (50.6 to 85.3) | 6.7 (0.8 to 22.1) | 92.9 (66.1 to 99.8) |
| percentage of subjects achieving ETR | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Undetectable HCV RNA at Completion of Drug Administration (ETR, End-of-treatment Response) | 76.7 (57.7 to 90.1) | 30.0 (14.7 to 49.4) | 85.7 (57.2 to 98.2) |
| percentage of subjects achieving SVR12 | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Undetectable HCV RNA at 12 Weeks After Completion of Drug Administration | 66.7 (47.2 to 82.7) | 20.0 (7.7 to 38.6) | 71.4 (41.9 to 91.6) |
| log IU/mL | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Baseline | 6.73 (6.40 to 7.15) | 6.83 (6.55 to 7.15) | 6.05 (5.45 to 6.75) |
| Day2 | 4.15 (3.80 to 4.80) | 5.65 (5.20 to 6.10) | 3.80 (3.10 to 4.40) |
| Day3 | 3.35 (3.00 to 3.60) | 4.85 (4.40 to 5.30) | 2.80 (2.30 to 3.30) |
| 1Week | 2.40 (1.90 to 2.80) | 5.30 (4.50 to 5.70) | 1.25 (0.50 to 2.00) |
| 2Weeks | 1.30 (1.00 to 1.80) | 4.60 (3.70 to 5.30) | 0.50 (0.50 to 1.40) |
| 3Weeks | 0.50 (0.50 to 1.00) | 3.70 (2.90 to 4.80) | 0.50 (0.50 to 0.50) |
| 4Weeks | 0.50 (0.50 to 0.75) | 3.20 (2.00 to 4.20) | 0.50 (0.50 to 0.50) |
| 12Weeks | 0.50 (0.50 to 0.50) | 2.75 (0.50 to 4.75) | 0.50 (0.50 to 0.50) |
| End of treatment | 0.50 (0.50 to 0.50) | 3.20 (0.50 to 5.60) | 0.50 (0.50 to 0.50) |
| Follow-up 12weeks | 0.50 (0.50 to 6.00) | 6.20 (5.00 to 6.70) | 0.50 (0.50 to 0.50) |
| Follow-up 24weeks | 0.50 (0.50 to 6.60) | 6.20 (5.40 to 6.80) | 0.50 (0.50 to 0.50) |
To examine the emergence of resistance-associated variants after MP-424 administration.
| participants | MP-424+RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|
| V36M | 1 | 0 |
| T54A | 1 | 0 |
| T54S,A156T,V36A | 1 | 0 |
| T54A,R155W | 0 | 1 |
| Not detected | 5 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MP-424+RBV+IFN Beta, Genotype1 | — | 4/30 (13.3%) | 30/30 (100%) |
| RBV+IFN Beta, Genotype1 | — | 3/30 (10%) | 30/30 (100%) |
| MP-424+RBV+IFN Beta, Genotype2 | — | 5/14 (35.7%) | 14/14 (100%) |
| Event | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 0/30 | 1/14 |
| AnaemiaBlood and lymphatic system disorders | 0/30 | 0/30 | 1/14 |
| CataractEye disorders | 0/30 | 0/30 | 1/14 |
| Optic nerve disorderEye disorders | 0/30 | 0/30 | 1/14 |
| Renal impairmentRenal and urinary disorders | 0/30 | 0/30 | 1/14 |
| Blood bilirubin increasedInvestigations | 0/30 | 0/30 | 1/14 |
| Foot fractureInjury, poisoning and procedural complications | 0/30 | 0/30 | 1/14 |
| PneumoniaInfections and infestations | 1/30 | 0/30 | 0/14 |
| Chronic sinusitisInfections and infestations | 0/30 | 1/30 | 0/14 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 | 0/30 | 0/14 |
| Event | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 |
|---|---|---|---|
| PyrexiaGeneral disorders | 22/30 | 26/30 | 14/14 |
| AnaemiaBlood and lymphatic system disorders | 25/30 | 17/30 | 11/14 |
| Blood uric acid increasedInvestigations | 13/30 | 5/30 | 10/14 |
| MalaiseGeneral disorders | 18/30 | 14/30 | 7/14 |
| HeadacheNervous system disorders | 14/30 | 15/30 | 6/14 |
| RashSkin and subcutaneous tissue disorders | 13/30 | 5/30 | 7/14 |
| InsomniaPsychiatric disorders | 8/30 | 6/30 | 6/14 |
| NasopharyngitisInfections and infestations | 8/30 | 12/30 | 4/14 |
| NauseaGastrointestinal disorders | 12/30 | 6/30 | 4/14 |
| Blood creatinine increasedInvestigations | 12/30 | 0/30 | 5/14 |
| Age, Continuous(years) | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 | Total |
|---|---|---|---|---|
| Mean | 60.5 ± 6.4 | 57.6 ± 10.5 | 55.4 ± 7.7 | 58.4 ± 8.7 |
| Sex: Female, Male(Participants) | MP-424+RBV+IFN Beta, Genotype1 | RBV+IFN Beta, Genotype1 | MP-424+RBV+IFN Beta, Genotype2 | Total |
|---|---|---|---|---|
| Female | 22 | 21 | 9 | 52 |
| Male | 8 | 9 | 5 | 22 |
The record gives a start of Dec 2012, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2018, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Ribavirin · Interferon beta · Interferon beta-1b · Interferon beta-1a